![]() "Gene Writers have the potential to revolutionize the treatment of cystic fibrosis and to deliver multiple new medicines that introduce a full length CFTR sequence, or to make true corrections of pathogenic alleles in the CFTR sequence." "The collaboration of Pioneering Medicines and the Cystic Fibrosis Foundation will support development of Gene Writers designed to give people living with cystic fibrosis functional CFTR genes, with the goal of restoring normal, healthy lung function," said Paul Biondi, President, Pioneering Medicines and Executive Partner, Flagship Pioneering. We hope our collaboration leads to treatments and cures for cystic fibrosis." "The Cystic Fibrosis Foundation’s extensive network of scientists, companies, and clinicians knowledgeable about cystic fibrosis will help accelerate screening and development of our cystic fibrosis-targeting Gene Writers. "We’re excited to work with the Cystic Fibrosis Foundation, the world’s leader in supporting breakthrough technologies for cystic fibrosis," said Geoffrey von Maltzahn, Ph.D, Co-Founder and CEO of Tessera, and General Partner at Flagship Pioneering. Furthermore, current treatments are ineffective for about 10% of individuals living with cystic fibrosis. While major advances have been made over the past decade that have led to more therapeutic options for individuals living with cystic fibrosis, a curative approach is still lacking. It affects approximately 70 thousand people globally. Cystic fibrosis is an inherited genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that cause persistent and worsening lung congestion and infections that limit a person’s ability to breathe. Gene Writers make precise single nucleotide changes, small insertions and deletions, and can replace entire genes in a programmable way to correct the genetic code driving disease. The Gene Writers are part of a portfolio of technologies that Pioneering Medicines has assembled to treat cystic fibrosis as part of a broader collaboration with the Cystic Fibrosis Foundation. Tessera’s Gene Writing TM Technology is Designed to Simultaneously Correct Multiple Genetic Mutations as well as to Write Genes in Their EntiretyĬAMBRIDGE, Mass., November 03, 2021-( BUSINESS WIRE)-Tessera Therapeutics today announced a treatment-focused collaboration with the Cystic Fibrosis Foundation using Tessera’s Gene Writing technology to rewrite the genetic codes that cause cystic fibrosis.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |